Genmab — April 2019
-
@Sukkeralf did you see BMS say anything about Humax IL8 in their earnings?
-
Dr. Durie on Dara SC in the middle of the video
(again nothing we don't know...) https://www.youtube.com/watch?v=a8_MB7o0MZo -
From SG transcript: GSK has some fantastic data in multiple myeloma with the BCMA antibody drug conjugate. And what we hear from them is they're planning to submit in the second half of this year. And we're delighted through the impact in multiple myeloma. That is a potential large market. And they also are doing many other trials, including frontline. And so, that potentially could be a really big drug for GSK and really beneficial to patients and to Seattle genetics.
-
-
While RTOR currently is being piloted for only the most straightforward supplemental applications, future expansion to more complex supplements or to NEW molecular entities (NME). Måske det, de har i tankerne med accellerated https://www.focr.org/news/pink-sheet-real-time-oncology-review-has-sponsors-rethinking-what-data-share-us-fda-and-when
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind